The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adjuvant WIDER: A phase 3b trial of ribociclib (RIB) + endocrine therapy (ET) as adjuvant treatment (tx) in a close-to-clinical-practice patient (pt) population with HR+/HER2- early breast cancer (EBC).
 
Stephanie Graff
Stock and Other Ownership Interests - HCA Healthcare
Honoraria - Wolters Kluwer
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Lilly; Menarini; Novartis; Pfizer
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst)
Other Relationship - Dr. Susan Love Foundation for Breast Cancer Research
(OPTIONAL) Uncompensated Relationships - The Dempsey Center
 
Fatima Cardoso
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Celgene; Daiichi Sankyo; Eisai; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline; IQvia; Macrogenics; Medscape; Merck Sharp & Dohme; Merus; Mundipharma; Mylan; Novartis; Pfizer; Pierre Fabre; Prime Oncology; Roche; Samsung Bioepis; Sanofi; Seagen; Teva; touchIME
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer; Roche
 
Hope Rugo
Honoraria - Chugai Pharma; Mylan/Viatris
Consulting or Advisory Role - Bristol Meyer; Napo Pharmaceuticals; Sanofi
Research Funding - Ambryx (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Hoffmann-La Roche AG/Genentech, Inc (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Stemline Therapeutics (Inst)
 
Christine Brezden-Masley
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Lilly; Merck; Mylan; Novartis Canada Pharmaceuticals Inc; Pfizer; Roche Canada; Sanofi; Sanofi; Seagen; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Duchesnay; Gilead Sciences; Lilly; Merck; Mylan; Novartis Canada Pharmaceuticals Inc; Pfizer; Roche Canada; Sanofi; Seagen; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst); Novartis Canada Pharmaceuticals Inc (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Knight Pharmaceuticals; Knight Pharmaceuticals
 
Gustavo Werustsky
Honoraria - Novartis
 
Debasish Tripathy
Consulting or Advisory Role - Ambrx; AstraZeneca; BeiGene; Genomic Health; Gilead Sciences; GlaxoSmithKline; Jazz Pharmaceuticals; Menarini; Novartis; OncoPep; Personalis; Pfizer; Roche; Sermonix Pharmaceuticals; Zetagen
Research Funding - Ambrx (Inst); Novartis (Inst); Pfizer (Inst); Polyphor (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis
 
Joyce O'Shaughnessy
Honoraria - AADi; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Oncology; DualityBio; Eisai; Ellipses Pharma; Exact Sciences; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; HiberCell; Jazz Pharmaceuticals; Johnson & Johnson; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Sanofi; Seagen; Stemline Therapeutics; Summit Therapeutics; Tempus; Tersera
Consulting or Advisory Role - AADi; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Oncology; DualityBio; Eisai; Ellipses Pharma; Exact Sciences; G1 Therapeutics; Genentech; Gilead Sciences; Guardant Health; HiberCell; Jazz Pharmaceuticals; Johnson & Johnson; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Sanofi; Seagen; Stemline Therapeutics; Summit Therapeutics; Tempus; Tersera
Travel, Accommodations, Expenses - Aptitude Health; Daiichi Sankyo; DAVA Oncology; Lilly; Merck; Novartis; Roche
 
Cynthia Ma
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Danatlas; Foundation Medicine; Genzyme; Lilly; Merck; Merck; Novartis; Olaris; Pfizer; Regor Therapeutics Group; Stemline Therapeutics; Stemline Therapeutics; Tersera; Tersera
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate: Authorship - served as a co-author on the subject of endocrine therapy for metastatic breast cancer and receive compensation as an author, less than a few hundred dollars a year. It does not affect my patient care or research.
 
Michael Danso
Honoraria - Amgen
Consulting or Advisory Role - Agendia; AstraZeneca; bioTheranostics; Genentech; Gilead Sciences; Immunomedics; Lilly; Novartis; Pfizer; Puma Biotechnology; Sanofi; Seagen; Stemline Therapeutics
 
Yen-Shen Lu
Honoraria - AstraZeneca; Daiichi Sankyo/UCB Japan; Eisai; EuroPharma; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis
 
Gul Basaran
No Relationships to Disclose
 
Mario Campone
Honoraria - Pfizer (Inst)
Consulting or Advisory Role - Pfizer (Inst)
Speakers' Bureau - Lilly (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer
 
Michelino De Laurentiis
Stock and Other Ownership Interests - Arvinas
Honoraria - AstraZeneca; Daiichi Sankyo Europe GmbH; Exact Sciences; Gilead Sciences; Ipsen; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; TOMA Biosciences; Veracyte
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Gilead Sciences; Ipsen; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Speakers' Bureau - Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Genzyme (Inst); Lilly; MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MAJ3 Capital
Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung; Steamline Therapeutics
Consulting or Advisory Role - Abbvie; AstraZeneca; Athenex; Bioasis; Biocon; Bioinvent; BioNTech SE; Boehringer Ingelheim; Bridgebio; Celgene; Cellestia Biotech; Circle Pharma; Clovis Oncology; Daiichi Sankyo; Delcath Systems; Ellipses Pharma; ERYTECH Pharma; Expres2ion Biotechnologies; GEMoaB; Gilead Sciences; GlaxoSmithKline; Hexagon Bio; HiberCell; Jazz Pharmaceuticals; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); Astrazeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Merck Sharp&Dhome; Novartis; Pfizer; Roche; Steamline Therapeutics
 
Valarie Worthy
No Relationships to Disclose
 
Melissa Gao
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Benoit Musel
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Fen Ye
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Kristyn Pantoja
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Peter Fasching
Honoraria - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; SeaGen
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Guardant Health; Hexal; Lilly; Menarini Group; Merck Sharp & Dohme; Mylan; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; Veracyte
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst); Pfizer (Inst); Roche